People · Operator
Named in public records as an officer, director or promoter · active 2018–2020 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Landos Biopharma, Inc. | — | Biotechnology | Series C | $60.3M | $2.5B | 2019 |
| Quellis Biosciences, Inc. | — | Biotechnology | Series A | $13.1M | $29.7M | 2018 |
Christopher Garabedian at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Garabedian on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan Violin | 1 | 5 |
| Frederick Callori | 1 | 4 |
| Peter Harwin | 1 | 4 |
| Tomas Kiselak | 1 | 3 |
| Josep Bassaganya-Riera | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.